Mangalathu S. Rajeevan, PhD, works for the National Center for Emerging and Zoonotic Infectious Diseases at the Centers for Disease Control and Prevention (CDC).
Notable studies[edit | edit source]
- 2004, Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome(Abstract)
- 2009, Transcriptional control of complement activation in an exercise model of chronic fatigue syndrome(Full text)
- 2013, Acute psychosocial stress-mediated changes in the expression and methylation of perforin in chronic fatigue syndrome(Full Text)
- 2015, Pathway-focused genetic evaluation of immune and inflammation related genes with chronic fatigue syndrome(Full Text)
- 2017, Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study(Full Text)
Talks and interviews[edit | edit source]
Online presence[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- Rajeevan, Mangalathu S.; Jones, James F.; Vernon, Suzanne D.; Unger, Elizabeth R.; Steinau, Martin (Nov 1, 2004). "Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome". Journal of Molecular Medicine. 82 (11): 750–755. doi:10.1007/s00109-004-0586-4. ISSN 1432-1440.
- Sorensen, Bristol; Jones, James F; Vernon, Suzanne D; Rajeevan, Mangalathu S (Jan 2009). "Transcriptional Control of Complement Activation in an Exercise Model of Chronic Fatigue Syndrome". Molecular Medicine. 15 (1-2): 34–42. doi:10.2119/molmed.2008.00098. PMC . PMID 19015737.
- Falkenberg, Virginia R; Whistler, Toni; Murray, Janna R; Unger, Elizabeth R; Rajeevan, Mangalathu S (2013). "Acute Psychosocial Stress-Mediated Changes in the Expression and Methylation of Perforin in Chronic Fatigue Syndrome". Genetics and Epigenetics. 5: 1–9. doi:10.4137/GEG.S10944. PMC . PMID 25512702.
- Rajeevan, Mangalathu S.; Dimulescu, Irina; Murray, Janna; Falkenberg, Virginia R.; Unger, Elizabeth R. (Aug 1, 2015). "Pathway-focused genetic evaluation of immune and inflammation related genes with chronic fatigue syndrome". Human Immunology. 76 (8): 553–560. doi:10.1016/j.humimm.2015.06.014. ISSN 0198-8859.
- Unger, Elizabeth R.; Lin, Jin-Mann S.; Tian, Hao; Natelson, Benjamin H; Lange, Gudrun; Vu, Diana; Blate, Michelle; Klimas, Nancy G.; Balbin, Elizabeth G.; Bateman, Lucinda; Allen, Ali; Lapp, Charles W.; Springs, Wendy; Kogelnik, Andreas M.; Phan, Catrina C.; Danver, Joan; Podell, Richard N.; Fitzpatrick, Trisha; Peterson, Daniel L.; Gottschalk, C. Gunnar; Rajeevan, Mangalathu S.; MCAM Study Group (2017), "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.", American Journal of Epidemiology, 1–10, doi:10.1093/aje/kwx029
Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.
chronic fatigue syndrome (CFS) - A fatigue-based illness. The term CFS was invented invented by the U.S. Centers for Disease Control as an replacement for myalgic encephalomyelitis (ME). Some view CFS as a neurological disease, others use the term for any unexplained long-term fatigue. Sometimes used as a the term as a synonym of myalgic encephalomyelitis, despite the different diagnostic criteria.
myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.